Multiple myelonna remains fatal, and the disease relapses despite the nnost aggressive treatment available today. The long-term goal of this project Is to develop more effective cytostatic therapies to eradicate myelonia cells. The candidate has developed the monoclonal antibodies specific for human beta2- microglobulin (anli-beta2M mAbs), which have strong apoptotic activity in myeloma cells. She hypothesizes that antl-beta2M mAbs may be used as therapeutic agents to treat patients with myeloma. In the past two years, she has made a great progress In this research. Related studies have been published In fhe high impact journals and/or presented in the national and/or intemational academic meetings. In the next stage, the candidate will further examine the mechanisms of mAb-induced apoptosis in myeloma cells, and enhance the efficacy of anti-beta2M mAbs by immune effector cells or molecules or by combining with novel antlmyeloma agents. Completing these novel studies will lead to a better understanding ofthe role of antibeta2M mAbs in myeloma and may provide another avenue for augmenting currently available therapies for treating MM and potentially olher malignancies. The overall caree goal of candidate Is to become an outstanding independent Investigator In the field of myeloma translational research. In the period of mentor phase, she has completed lots and series of training, aiming to an independent investigator, as scheduling In her proposal. In the next phase, she Intends to continue to her career development, and proposes to acquire the necessary additional knowtedge and skills in myeloma translatlonal research and acquire the skills of Independently carrying out the research program. Moreover, she will ultllize the ongoing observational research as a platform for successful applications for federal fundings of myeloma studies In the period of the ROO phase. Recognized with her outstanding research capacity, the candidate has been recruited as a tenure-track assistant professor by the University of Texas, M.D. Anderson Cancer Center and begin on September 1, 2011.
(See Insfructions): Based on previous studies, the candidate strongly believes that anti-beta2M mAbs are a powerful therapeutic agent to treat myeloma patients in cllnlc. Moreover, the candidate has outstanding training and formulated research and career development plan. In addition, the University of Texas, M.D. Anderson Cancer Center has recruited the candidate as a tenure-track assistant professor. Thus, continuing the ROO Avvard will support the candidate career development to be a successful independent investigator.
|Zhang, Mingjun; He, Jin; Liu, Zhiqiang et al. (2015) Anti-Î²â‚‚-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget 6:8567-78|
|Liu, Zhiqiang; Xu, Jingda; He, Jin et al. (2014) A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124:2061-71|
|He, Zhimin; He, Jin; Liu, Zhiqiang et al. (2014) MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie 106:24-32|
|He, Jin; Liu, Zhiqiang; Zheng, Yuhuan et al. (2012) p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res 72:6393-402|
|Yang, J; He, J; Wang, J et al. (2012) Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26:2114-23|
|Zheng, Yuhuan; Yang, Jing; Qian, Jianfei et al. (2012) Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90:695-706|
|Yang, Jing; Yi, Qing (2011) Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am J Blood Res 1:22-33|
|Yang, Jing; Yi, Qing (2010) Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 116:1638-45|